TY - JOUR
T1 - Real-life effect of long-acting β2-agonist withdrawal in patients with controlled step 3 asthma
AU - Jabbal, Sunny
AU - Manoharan, Arvind
AU - Anderson, William
AU - Lipworth, Joseph
AU - Lipworth, Brian
N1 - Dr Anderson reported receiving honorarium and travel grants from AstraZeneca. Dr Lipworth reported receiving consulting fees from Chiesi, Dr Reddy's Laboratories, Cipla, and Sandoz, speaker fees from Meda, and grant support from Meda, Teva, and Roche.
PY - 2016/10
Y1 - 2016/10
N2 - Approximately 45% of patients with asthma in the United Kingdom are receiving step 3 or higher therapy,1 most commonly inhaled corticosteroids (ICSs) and long-acting β2-agonists (LABAs). The 2016 Global Initiative for Asthma (GINA) guidelines propose a cycle of assessment, stepwise adjustment of treatment, and review of response to ascertain the lowest treatment to achieve control.2 In addition, the US Food and Drug Administration advocates stopping use of LABAs once asthma control is achieved and maintained and switching to ICS monotherapy.
AB - Approximately 45% of patients with asthma in the United Kingdom are receiving step 3 or higher therapy,1 most commonly inhaled corticosteroids (ICSs) and long-acting β2-agonists (LABAs). The 2016 Global Initiative for Asthma (GINA) guidelines propose a cycle of assessment, stepwise adjustment of treatment, and review of response to ascertain the lowest treatment to achieve control.2 In addition, the US Food and Drug Administration advocates stopping use of LABAs once asthma control is achieved and maintained and switching to ICS monotherapy.
U2 - 10.1016/j.anai.2016.07.022
DO - 10.1016/j.anai.2016.07.022
M3 - Letter
C2 - 27519578
SN - 1081-1206
VL - 117
SP - 430
EP - 431
JO - Annals of Allergy, Asthma and Immunology
JF - Annals of Allergy, Asthma and Immunology
IS - 4
ER -